DK0804237T3 - Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 - Google Patents

Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4

Info

Publication number
DK0804237T3
DK0804237T3 DK95908741T DK95908741T DK0804237T3 DK 0804237 T3 DK0804237 T3 DK 0804237T3 DK 95908741 T DK95908741 T DK 95908741T DK 95908741 T DK95908741 T DK 95908741T DK 0804237 T3 DK0804237 T3 DK 0804237T3
Authority
DK
Denmark
Prior art keywords
humanized antibodies
adhesion molecule
leukocyte adhesion
molecule vla
vla
Prior art date
Application number
DK95908741T
Other languages
Danish (da)
English (en)
Inventor
Jose Saldanha
Theodore A Yednock
Mary M Bendig
Olivier J Leger
Tarran S Jones
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of DK0804237T3 publication Critical patent/DK0804237T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95908741T 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 DK0804237T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25

Publications (1)

Publication Number Publication Date
DK0804237T3 true DK0804237T3 (da) 2006-10-16

Family

ID=22684288

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95908741T DK0804237T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4
DK06013916.9T DK1759709T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06013916.9T DK1759709T3 (da) 1994-01-25 1995-01-25 Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4

Country Status (21)

Country Link
EP (2) EP0804237B8 (enExample)
JP (5) JP4115517B2 (enExample)
KR (1) KR100367948B1 (enExample)
CN (1) CN1211123C (enExample)
AT (1) ATE333895T1 (enExample)
AU (1) AU703152B2 (enExample)
CA (1) CA2182013C (enExample)
DE (2) DE122006000043I1 (enExample)
DK (2) DK0804237T3 (enExample)
ES (2) ES2424292T3 (enExample)
FI (1) FI117509B (enExample)
FR (1) FR06C0024I2 (enExample)
HU (1) HU220799B1 (enExample)
LU (1) LU91271I2 (enExample)
MX (1) MX9602971A (enExample)
NL (1) NL300238I2 (enExample)
NO (3) NO319867B1 (enExample)
NZ (1) NZ279730A (enExample)
PL (1) PL181827B1 (enExample)
PT (1) PT804237E (enExample)
WO (1) WO1995019790A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000015247A2 (en) * 1998-09-14 2000-03-23 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
IL145898A0 (en) * 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200100651A (et) 1999-06-01 2003-02-17 Biogen, Inc. VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK2140881T3 (da) * 1999-12-16 2013-05-06 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
NZ535320A (en) 2002-02-25 2008-05-30 Elan Pharm Inc Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
CA2481747A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
AU2003298187B2 (en) * 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005061466A1 (ja) 2003-12-22 2005-07-07 Ajinomoto Co., Inc. 新規フェニルアラニン誘導体
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
US20080311119A1 (en) * 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
BRPI0820202B1 (pt) 2007-12-13 2018-05-08 Tokuyama Corp composição curável fotocrômica
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
MY162752A (en) 2009-03-20 2017-07-14 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
ME02793B (me) 2010-04-16 2018-01-20 Biogen Ma Inc Anti-vla-4 antitijela
CA2834900C (en) 2011-05-02 2021-03-02 Millennium Pharmaceuticals, Inc. Formulation for anti-.alpha.4.beta.7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126B1 (en) * 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
DK0625912T3 (da) * 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
PL181827B1 (pl) 2001-09-28
AU1696095A (en) 1995-08-08
JPH09508272A (ja) 1997-08-26
NO963097D0 (no) 1996-07-24
JP2009235078A (ja) 2009-10-15
JP5487382B2 (ja) 2014-05-07
ES2424292T3 (es) 2013-09-30
NZ279730A (en) 1998-04-27
NO2006008I1 (no) 2006-08-07
DE69535133T2 (de) 2008-08-21
KR970700513A (ko) 1997-02-12
MX9602971A (es) 1998-01-31
ATE333895T1 (de) 2006-08-15
NO319867B1 (no) 2005-09-26
EP0804237A1 (en) 1997-11-05
FI117509B (fi) 2006-11-15
HU9602019D0 (en) 1996-09-30
NO963097L (no) 1996-09-24
HUT75129A (en) 1997-04-28
DK1759709T3 (da) 2013-06-10
FI962958L (fi) 1996-09-24
EP0804237B8 (en) 2006-11-08
EP1759709B1 (en) 2013-02-27
NO2017040I1 (no) 2017-08-01
DE69535133D1 (de) 2006-09-07
FR06C0024I2 (fr) 2009-01-02
AU703152B2 (en) 1999-03-18
CA2182013A1 (en) 1995-07-27
WO1995019790A1 (en) 1995-07-27
CN1211123C (zh) 2005-07-20
PT804237E (pt) 2006-10-31
EP0804237A4 (en) 2003-04-16
KR100367948B1 (ko) 2003-07-12
JP2013173738A (ja) 2013-09-05
NL300238I1 (enExample) 2006-10-02
ES2270425T3 (es) 2007-04-01
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
NO2006008I2 (no) 2009-06-15
EP1759709A1 (en) 2007-03-07
LU91271I2 (fr) 2006-10-02
NO2017040I2 (no) 2018-08-28
JP2006045237A (ja) 2006-02-16
JP4115517B2 (ja) 2008-07-09
CA2182013C (en) 2007-07-17
EP0804237B1 (en) 2006-07-26
NL300238I2 (nl) 2007-05-01
PL315634A1 (en) 1996-11-25
JP2013165718A (ja) 2013-08-29
DE122006000043I1 (de) 2007-02-15
HU220799B1 (hu) 2002-05-28
FR06C0024I1 (enExample) 2006-10-13

Similar Documents

Publication Publication Date Title
DK1759709T3 (da) Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4
FI961285A0 (fi) CD40:n vasta-aineita
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
ATE531812T1 (de) Humanisierung von nager-antikörpern
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DE69526929D1 (de) Antikörperreinigung
DE59609954D1 (de) Katalytisch wirksame aktivatorkomplexe für persauerstoffverbindungen
MY154009A (en) Anti-alpha v beta 6 antibodies
DK1414861T3 (da) Humaniserede antistoffer mod ICAM-1, fremstilling og anvendelse heraf
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
IL141158A0 (en) A humanized immunoglobulin which binds to human von willebrand factor
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE69103214D1 (de) Verfahren zur Reinigung von Glycin.
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C